Cover Image

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Key Points. Independent prognostic impact of biological markers, notably TP53 and SF3B1 mutations, in CLL patients requiring therapy.NOTCH1 mutation as a predictive factor for reducedbenefit from the addition ofrituximab to FC chemotherapy.

Saved in:
Bibliographic Details
Main Authors: Stilgenbauer, Stephan (Author) , Schnaiter, Andrea Barbara (Author) , Paschka, Peter (Author) , Zenz, Thorsten (Author) , Rossi, Marianna (Author) , Döhner, Konstanze (Author) , Bühler, Andreas (Author) , Böttcher, Sebastian (Author) , Ritgen, Matthias (Author) , Kneba, Michael (Author) , Winkler, Dirk (Author) , Tausch, Eugen (Author) , Hoth, Patrick (Author) , Edelmann, Jennifer (Author) , Mertens, Daniel (Author) , Bullinger, Lars (Author) , Bergmann, Manuela (Author) , Kless, Sabrina (Author) , Mack, Silja (Author) , Jäger, Ulrich (Author) , Patten, Nancy (Author) , Wu, Lin (Author) , Wenger, Michael K. (Author) , Fingerle-Rowson, Günter (Author) , Lichter, Peter (Author) , Cazzola, Mario (Author) , Wendtner, Clemens M. (Author) , Fink, Anna M. (Author) , Fischer, Kirsten (Author) , Busch, Raymonde (Author) , Hallek, Michael (Author) , Döhner, Hartmut (Author)
Format: Article (Journal)
Language:English
Published: March 20, 2014
In: Blood
Year: 2014, Volume: 123, Issue: 21, Pages: 3247-3254
ISSN:1528-0020
DOI:10.1182/blood-2014-01-546150
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2014-01-546150
Verlag, lizenzpflichtig, Volltext: https://ashpublications.org/blood/article/123/21/3247/32778/Gene-mutations-and-treatment-outcome-in-chronic
Get full text
Author Notes:Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael K. Wenger, Günter Fingerle-Rowson, Peter Lichter, Mario Cazzola, Clemens M. Wendtner, Anna M. Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, and Hartmut Döhner
Description
Summary:Key Points. Independent prognostic impact of biological markers, notably TP53 and SF3B1 mutations, in CLL patients requiring therapy.NOTCH1 mutation as a predictive factor for reducedbenefit from the addition ofrituximab to FC chemotherapy.
Item Description:Gesehen am 17.08.2020
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood-2014-01-546150

Similar Items